Identification of a Highly Lethal V3+ TP53+ Subset in ALK+ Lung Adenocarcinoma

International Journal of Cancer - United States
doi 10.1002/ijc.31893
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

Uncommon Features of Surgically Resected ALK-positive Cavitary Lung Adenocarcinoma: A Case Report

Surgical Case Reports
2017English

Identification of a Multidimensional Transcriptome Prognostic Signature for Lung Adenocarcinoma

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2019English

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

ALK Fusion Protein Expression in Lung Adenocarcinoma and Its Correlation With EGFR Protein Expression

Madridge Journal of Oncogenesis
2018English

Comment on ‘Testing for ALK Rearrangement in Lung Adenocarcinoma: A Multicenter Comparison of Immunohistochemistry and Fluorescent in Situ Hybridization’

Modern Pathology
Forensic MedicinePathology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy